Davies, Melanie J.
Drexel, Heinz
Jornayvaz, François R.
Pataky, Zoltan
Seferović, Petar M.
Wanner, Christoph
Article History
Received: 8 December 2021
Accepted: 14 May 2022
First Online: 4 August 2022
Declarations
:
: Not applicable—no novel research is described in this manuscript.
: Not applicable—as no novel research is described in this manuscript, there are no study subjects to provide consent.
: MJD reported board membership and consultancy fees from Novo Nordisk, Sanofi-Aventis, Lilly, Merck, Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Servier, and Janssen. MJD reported institutional grants from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim and Janssen. MJD reported payment for lectures or speaker bureaus from Novo Nordisk, Sanofi-Aventis, Lilly, Merck, Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Mitsubishi Tanabe Pharma, and Takeda Pharmaceuticals International.HD declares no conflicts of interest.FRJ has received consulting honoraria from Boehringer Ingelheim, Mundipharma, Astra Zeneca, Novo Nordisk, MSD, Lilly, and Sanofi.DKM has had leadership roles in clinical trials for AstraZeneca, Boehringer Ingelheim, Eisai, Esperion, GlaxoSmithKline, Janssen, Lexicon, Merck & Co., Inc., Novo Nordisk, CSL Behring, and Sanofi USA; and has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Lilly USA, Merck & Co., Inc., Pfizer, Novo Nordisk, Metavant, Afimmune, and Sanofi.ZP has received consulting honoraria from Boehringer Ingelheim, Novo Nordisk, and Sanofi.PMS has received honorarium for lectures for Medtronic, Abbott, Servier, Astra Zeneca, and Respicardia; Boehringer Ingelheim consultancy agreement and honorarium for lecture, Novartis consultancy agreement and honorarium for lecture, Vifor Pharma consultancy agreement.CW has received personal fees from Boehringer Ingelheim, Akebia, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Gilead, Merck Sharpe Dohme, Mundipharma, Sanofi-Genzyme, and Vifor Fresenius.